Aimmune Therapeutics (AIMT) Receives a Hold from Stifel Nicolaus

By Carrie Williams

Stifel Nicolaus analyst Derek Archila maintained a Hold rating on Aimmune Therapeutics (AIMTResearch Report) today. The company’s shares closed last Monday at $24.32.

Archila commented:

“We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not “new” news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ “worst case” scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk.”

According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.1% and a 29.7% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.

Aimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.60.

See today’s analyst top recommended stocks >>

The company has a one-year high of $36.12 and a one-year low of $16.95. Currently, Aimmune Therapeutics has an average volume of 604.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.